<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The COVID-19 pandemic is still a burden to the global health care system, affecting its capacity to maintain essential health services. Even though specific treatment and prevention options are available, the SARS-CoV-2 virus keeps accumulating mutations over time and challenging the efficiency of vaccines, causing new outbreaks and increasing hospitalisation. Early studies suggest that mortality from COVID-19 is increased by age and certain comorbidities. Thus, the goal of this study was to analyse patients hospitalised with COVID-19 pneumonia in terms of age, sex, and comorbidities. Additionally, the influence of treatment with Remdesivir and vaccination on hospitalisation duration and disease outcome was also analysed. The results showed that lethal disease outcome is mainly increased by age and gender, where older and male patients are at a higher risk. There were less deaths in patients with primary arterial hypertension. Other comorbidities did not have a statistically significant influence on disease outcome. Among those who survived, a higher number of patients had been treated with Remdesivir. Vaccination did not have an impact on disease outcome. It could be concluded that older and male patients are the risk group with a worse disease outcome. Treatment with Remdesivir shows a positive effect on disease outcome, although further detailed analysis is necessary.</p>
</abstract>

The COVID-19 pandemic is still a burden to the global health care system, affecting its capacity to maintain essential health services. Even though specific treatment and prevention options are available, the SARS-CoV-2 virus keeps accumulating mutations over time and challenging the efficiency of vaccines, causing new outbreaks and increasing hospitalisation. Early studies suggest that mortality from COVID-19 is increased by age and certain comorbidities. Thus, the goal of this study was to analyse patients hospitalised with COVID-19 pneumonia in terms of age, sex, and comorbidities. Additionally, the influence of treatment with Remdesivir and vaccination on hospitalisation duration and disease outcome was also analysed. The results showed that lethal disease outcome is mainly increased by age and gender, where older and male patients are at a higher risk. There were less deaths in patients with primary arterial hypertension. Other comorbidities did not have a statistically significant influence on disease outcome. Among those who survived, a higher number of patients had been treated with Remdesivir. Vaccination did not have an impact on disease outcome. It could be concluded that older and male patients are the risk group with a worse disease outcome. Treatment with Remdesivir shows a positive effect on disease outcome, although further detailed analysis is necessary.

Overview and Outcomes of Patients Hospitalised with COVID-19 Pneumonia in Rīga East University Hospital

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution 4.0 International License.

The COVID-19 pandemic is still a burden to the global health care system, affecting its capacity to maintain essential health services. Even though specific...

Overview and Outcomes of Patients Hospitalised with COVID-19 Pneumonia in Rīga East University Hospital

Publié en ligne: 04 mars 2024

Pages: 10 - 15

Reçu: 04 oct. 2022

Accepté: 18 oct. 2023

DOI: https://doi.org/10.2478/prolas-2024-0002

Mots clés
comorbidities, age, gender, remdesivir, vaccination, disease outcome

© 2024 Reinis Rugājs et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Overview and Outcomes of Patients Hospitalised with COVID-19 Pneumonia in Rīga East University Hospital

Publié en ligne: 04 mars 2024

Pages: 10 - 15

Reçu: 04 oct. 2022

Accepté: 18 oct. 2023

DOI: https://doi.org/10.2478/prolas-2024-0002

Mots cléscomorbidities, age, gender, remdesivir, vaccination, disease outcome

© 2024 Reinis Rugājs et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Mots clés
comorbidities, age, gender, remdesivir, vaccination, disease outcome